Monte Rosa Therapeutics/$GLUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Ticker
$GLUE
Sector
Primary listing
Employees
150
Headquarters
Website
GLUE Metrics
BasicAdvanced
$1.3B
-
-$0.46
1.64
-
Price and volume
Market cap
$1.3B
Beta
1.64
52-week high
$25.77
52-week low
$3.50
Average daily volume
1.1M
Financial strength
Current ratio
6.123
Quick ratio
6.053
Long term debt to equity
14.929
Total debt to equity
16.816
Profitability
EBITDA (TTM)
-45.852
Gross margin (TTM)
-8.11%
Net profit margin (TTM)
-31.23%
Operating margin (TTM)
-43.83%
Effective tax rate (TTM)
2.76%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-7.64%
Return on equity (TTM)
-16.94%
Valuation
Price to revenue (TTM)
10.552
Price to book
4.42
Price to tangible book (TTM)
4.42
Price to free cash flow (TTM)
-47.46
Free cash flow yield (TTM)
-2.11%
Free cash flow per share (TTM)
-0.331
Growth
Revenue change (TTM)
63.54%
Earnings per share change (TTM)
-52.73%
3-year earnings per share growth (CAGR)
-41.29%
What the Analysts think about GLUE
Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.
GLUE Financial Performance
Revenues and expenses
GLUE Earnings Performance
Company profitability
GLUE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Monte Rosa Therapeutics stock?
Monte Rosa Therapeutics (GLUE) has a market cap of $1.3B as of March 26, 2026.
What is the P/E ratio for Monte Rosa Therapeutics stock?
The price to earnings (P/E) ratio for Monte Rosa Therapeutics (GLUE) stock is 0 as of March 26, 2026.
Does Monte Rosa Therapeutics stock pay dividends?
No, Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders as of March 26, 2026.
When is the next Monte Rosa Therapeutics dividend payment date?
Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.